Kodiak Sciences Inc · NASDAQ:KOD
Kodiak Sciences — Barclays Global Healthcare Conference 2021
63 slides from Kodiak Sciences's conference presentation, Mar 10, 2021
Slide 1: The Ophthalmology Medicines Company
THE OPHTHALMOLOGY MEDICINES COMPANY Barclays Global Healthcare Conference March 10, 2021
Slide 2: Special Note Regarding Forward-Looking Statements
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and
Slide 3: Where We Are Today
K S I - 30 1 C L I N I C A L E X P E R IE N C E Clinical data from ~2,000 injections in ~500 patients representing ~350 patient-years of exposure in representative populations in wAMD, DME and RVO ▪ Safety: Tracking with current standard of care (Lucentis, Eylea) ▪ Efficacy: Vision & retinal anatomy
Slide 4: Our Mission
T H E O P H T H A L M O L O G Y M E D I C I N E S C O M P A N Y OUR MISSION 1 TRAILBLAZING 2 GENERATION 2.0 3 SINGULAR FOCUS IN SCIENCE MEDICINES OPHTHALMOLOGY Our creative and Our challenge to the Our 24 / 7 / 365 thoughtful foundation status quo 4
Slide 5: A Pipeline of ABCs for Retina
A PIPELINE MONOSPECIFIC 1 Molecule, 1 Target OF ABC S FOR Antibody conjugated to phosphorylcholine biopolymer RETINA KSI-301 inhibits VEGF— In Phase 3 clinical development BISPECIFIC 1 Molecule, 2 Targets Kodiak’s deepening pipeline Bispecific antibody conjugated to phosphorylcholine biopolymer of m
Slide 6: Focused on Developing ABC Medicines for High Prevalence Retinal Diseases
T H E O P H T H A L M O L O G Y M E D I C I N E S C O M P A N Y FOCUSED ON DEVELOPING ABC MEDICINES FOR HIGH PREVALENCE RETINAL DISEASES KSI-301 AND KSI-501 FOR RETINAL VASCULAR DISEASES A GROWING $11B MARKET WITH CLEAR UNMET NEEDS ▪ Wet age-related macular degeneration (wet AMD) remains a leading c
Slide 7: In Theory
F O C U S O N K S I - 3 0 1 Recommended dosing in first year: IN THEORY Ranibizumab Aflibercept 12 8 monthly bi-monthly after 3 monthly loading doses Intravitreal anti-VEGF PHASE III STUDY OFMARINA MONTHLY 1 ANTI-VEGF 1 agents improve & 10 Ranibizumab Lucentis 0.5 mg 0.5MG maintain vision when 5 Cha
Slide 8: In Practice
F O C U S O N K S I - 3 0 1 Without continuous high-intensity treatment, vision IN PRACTICE loss can begin after only 3 months of anti-VEGF therapy. This pattern is seen globally and with all current medicines. …yet in the real word, 10 EUROPE 1 No. of injections MEAN CHANGE IN VA (N = 2,227 patient
Slide 9: Retinal Thickness on OCT
F O C U S O N K S I - 3 0 1 Bimonthly anti-VEGF therapy results in WHY? disease activity between doses due to insufficient durability. Current, Generation 1.0 AFLIBERCEPT VIEW STUDIES 1 agents do not provide 0 disease control for long Ranibizumab RETINAL THICKNESS ON OCT MEAN CHANGE IN CENTRAL month
Slide 10: What Profile May Be Required to Meaningfully Change the Current Paradigm?
F O C U S O N K S I - 3 0 1 WHAT PROFILE MAY BE REQUIRED TO MEANINGFULLY CHANGE THE CURRENT PARADIGM? Durability Profile Maintenance Phase Loading Phase Efficacy Profile Safety Profile wAMD: >50% reach Q20W wAMD, DME, and RVO: Non- DME: >50% reach Q20W inferior to comparator Safety profile is in lin
Slide 11: Disruptive Durability with an Intravitreal Biologic
F O C U S O N K S I - 3 0 1 DISRUPTIVE DURABILITY WITH AN INTRAVITREAL BIOLOGIC: 2/3 OF PATIENTS ON A ≥6 -MONTH TREATMENT-FREE INTERVAL AT YEAR 1 IN WET AMD, DME AND RVO Interval at Year 1 Wet AMD DME RVO N = 50 N = 32 N = 32 1 month 2% 3% 3% 2 months 14% 3% 9% 3 months 6% 9% 13% 4 months 4% 6% 6% 5
Slide 12: Year 1 Data: Efficacy Aligned with Today's Medicines with Fewer Injections
F O C U S O N K S I - 3 0 1 YEAR 1 DATA: EFFICACY ALIGNED WITH TODAY’S MEDICINES WITH MEANINGFULLY FEWER INJECTIONS Year 1 Doses Visual Acuity Retinal Anatomy (OCT CST) Loading Individualized Mean △ From Mean BCVA Mean △ From Mean OCT Doses Doses Baseline at Year 1 at Year 1 Baseline at Year 1 CST a
Slide 13: Year 1 Data: Vision Improvements Dependent on Baseline Vision
F O C U S O N K S I - 3 0 1 YEAR 1 DATA: VISION IMPROVEMENTS SEEN IN ANTI -VEGF STUDIES ARE DEPENDENT ON BASELINE VISION WET AMD ~YEAR 1 BCVA Ph. 1b TENAYA LUCERNE HARRIER HAWK VIEW 1 VIEW 2 80 75 69.7 BCVA (Letters) 70 66.4 67.3 68.4 68.4 65.3 65.5 67.1 67.4 66.8 66.1 65 +5.7 63.6 62.5 63.2 +5.8 +5
Slide 14: ABC Platform
ANTIBODY BIOPOL YMER CONJUGATE ABC PLATFORM ™ Biologics precision-engineered for increased durability and efficacy SAME WHERE IT MATTERS o Clinically proven targets o Antibody-based biologic o Intravitreal: 25M+ injections annually +stable linkage = o Optically clear, no residues o Fast and potent c
Slide 15: KSI-301: Generation 2.0 Anti-VEGF
K S I - 3 0 1 : A N A N T I - V E G F A B C GENERATION 2.0 ANTI-VEGF KSI-301 KSI-301’s high molecular weight & formulation strength can provide an important dosing advantage Antibody Biopolymer Conjugate (ABC) Drug: RANIBIZUMAB AFLIBERCEPT BEVACIZUMAB (Lucentis) (Eylea) (Avastin) Recombinant Molecul
Slide 16: More Than the Sum of Its Parts
KSI-301 ANTIBODY BIOPOLYMER CONJUGATE “MORE THAN THE SUM OF ITS PARTS” Artistic representation Electron microscope of KSI-301 image of KSI-301 Class-leading Intraocular Excellent Retinal Deeper Inhibitory Fast Systemic Half-life1 Bioavailability2 Potency3 Clearance4 Primary human retinal cell-based
Slide 17: Our Goal with KSI-301
OUR GOAL Patient & Patient’s Family WITH KSI-301 Retina Specialist & Care Team Develop KSI-301 as a meaningfully Retina Practice Owner differentiated first-line treatment in each retinal vascular disease Payor Better meet the individual needs of Health System key stakeholders globally 17
Slide 18: Developing KSI-301 to Be First Line in Major Retinal Vascular Diseases
We are developing KSI-301 to be first line in the 4 major retinal vascular diseases Target enrollment exceeded Now Recruiting Enrollment Start 1H 2021 Recruitment closed First patients randomized in GLEAM / GLIMMER and BEACON Planned Non-Proliferative Wet AMD Diabetic Macular Edema Retinal Vein Occl
Slide 19: Building Capacity to Supply Rapid Market Uptake
KSI-301 COMMERCIAL MANUFACTURING BUILDING CAPACITY TO SUPPLY RAPID MARKET UPTAKE Case study on market adoption Can Eylea market share growth educate KSI-301 adoption? Worldwide anti-VEGF revenue Expected Year 1 manufacturing capacity to supply Billions of USD 8 2.5M+ doses with the ability to flex u
Slide 20: Our 2022 Vision
OUR 2022 VISION WET AMD RETINAL VEIN OCCLUSION 2022 DAZZLE Phase 2b/3 top-line data 2022 BEACON Phase 3 top-line data 2022 BLA filing 2022 BLA filing DIABETIC MACULAR EDEMA 2022 GLEAM / GLIMMER Phase 3 top-line data 2022 BLA filing 2022 KSI-501 anti-VEGF/IL-6 THE OPHTHALMOLOGY 2021 IND submitted MED
Slide 21: Milestones and KSI-301 Development Acceleration
MILESTONES AND KSI -301 DEVELOPMENT ACCELERATION 2023 2022 KSI-301 2021 KSI-301 • Potential regulatory KSI-301 2020 • DAZZLE wAMD pivotal study top-line readout approval for wAMD, DME ✓ Presentation of one-year and RVO in US and EU KSI-301 Phase 1b results in wet • RVO pivotal study AMD, DME and RVO
Slide 22: KSI-301 Accelerated Development Strategy
KSI-301 Accelerated Development Strategy 4 Pivotal Studies to support BLA with All 3 Major Anti-VEGF Indications Run Concurrently Today 2019 2020 2021 2022 2023 Phase 1b 121 treatment-naïve wAMD, DME, RVO patients Ongoing Safety, efficacy, durability - 18 months follow-up DAZZLE ~550 treatment naïve
Slide 23: Clinical Data
KSI-301 Clinical Data 130 patients dosed in Phase 1a/1b Program 168+ patient years of clinical experience 23
Slide 24: KSI-301 Phase 1b Study Design
KSI-301 Phase 1b Study Design Randomized, open label study to evaluate multidose safety, efficacy & durability wAMD (n=51) DME (n=35) RVO (n=35) Randomized 1:3 KSI-301 2.5 mg (50 mL) KSI-301 5 mg (100 mL) Loading Phase Durability Assessment Phase Extension Study Weeks 0 4 8 12 to 72 (months 3 to 18)
Slide 25: KSI-301 Phase 1b Retreatment Criteria
KSI-301 Phase 1b Retreatment Criteria ▪ wAMD – Increase in CST ≥75 µm with a decrease in BCVA of ≥ 5 letters compared to Week 12, OR – Decrease in BCVA of > 5 letters compared to Day 1, due to worsening wAMD activity, OR – Decrease in BCVA of ≥ 10 letters compared to the best prior BCVA, due to wors
Slide 26: Baseline Characteristics
Baseline Characteristics wAMD Cohort DME Cohort RVO Cohort Variable (n=51) (n=35) (n=35) Age, mean (SD), years 77.9 (10.5) 59.7 (11.7) 63.6 (12.6) Gender, n (%), female 32 (62.7) 14 (40.0) 13 (37.1) Race, n (%), White 48 (94.1) 28 (80.0) 31 (88.6) BCVA, mean (SD), ETDRS letters 63.3 (13.3) 66.8 (10.
Slide 27: wAMD Year 1 Data
KSI-301 Phase 1b wAMD Year 1 Data 27
Slide 28: Efficacy of KSI-301 in Wet AMD
Efficacy of KSI-301 in Wet AMD Change from baseline to Week 52 in mean BCVA & OCT 75 ETDRS letters 70 BCVA +5.7 65 20/40 60 0 4 8 12 16 20 24 Weeks 28 32 36 40 44 48 52 500 OCT CST 450 microns 400 -105 350 N=50 300 3.0 2.0 Loading doses Individualized doses mean injections Interim data; 2.5 & 5 mg d
Slide 29: Efficacy of KSI-301 in Wet AMD by PED Status
Efficacy of KSI-301 in Wet AMD change from baseline to Week 52 by PED status 75 +5.7 20/40 ETDRS letters 70 BCVA 65 +5.0 ⁓20/40 60 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Weeks 500 450 OCT CST microns 400 350 -105 -90 300 250 Interim data; 2.5 & 5 mg doses pooled. Observed data, include only patients
Slide 30: Durability of KSI-301 in Wet AMD
Durability of KSI-301 in Wet AMD 80% of patients received 2 or fewer retreatments in Year 1 100 54% of patients required only Percentage of patients (%) Mean injections 5.0 in Year 1 80 1 retreatment Individualized 60 54.0 2.0 doses 40 Monthly loading 3.0 doses 26.0 20 KSI-301 8.0 4.0 6.0 2.0 0 1 2
Slide 31: Durability of KSI-301 in Wet AMD: Retreatment Intervals
Durability of KSI-301 in Wet AMD Distribution of retreatment intervals at Year 1 100 66% of patients were on a 80 6-month treatment-free Percentage of patients (%) interval at Year 1 66.0 60 40 20 14.0 6.0 8.0 2.0 4.0 0 1 2 3 4 5 6 month months months months months months Treatment interval at Year
Slide 32: KSI-301 in wAMD: Majority Can Achieve 6-Month Durability
KSI-301 in wAMD: the majority of patients can achieve 6-month durability Loading Year 1 Year 2 Overall Time on Study (weeks) 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Interval at Year 1* n=50 1 KSI-301 3 2.5 mg 5 1 month 2% 7 (n=12) 9 11 2 months 14% 1 3 5 3 months or longer 84% 7 9 11 4 months or lo
Slide 33: Case Example: 6-Month Dosing Through Year 1 in Wet AMD
Case Example: 6-Month Dosing Through 1 Year KSI-301 in wet AMD 3 Loading doses Day 1 Day 1 (Pre-Treatment) Week 4 Week 8 OCT Images Week 12 1 month after 3 From Phase 1b Study +8 letters loading doses 4 total injections in Year 1 Week 32 6 months after 3 +12 letters loading doses Treatment Given Wee
Slide 34: Benchmarking in Treatment-Naïve wAMD
Benchmarking in treatment-naïve wAMD: KSI-301 Phase 1b “Generation 2.0” durability compared to Eylea long-interval RCT and Faricimab TENAYA/LUCERNE 75 Eylea RIVAL Study KSI-301 Phase 1b Study (Year 1) Faricimab TENAYA / LUCERNE On Each Treatment Interval (%) 60 Proportion of Patients 45 30 15 0 4 6
Slide 35: DAZZLE Study: Dosing as Infrequently as Every 20 Weeks
KSI-301 Phase 2b/3 wAMD DAZZLE Study Dosing with KSI-301 as infrequently as every 20 weeks* Wet AMD – Phase 1b DAZZLE pivotal study evaluates individualized Percentage Interval at Year 1 dosing of every 12, 16 or 20 weeks (n=50) 1 month 2% 2 months 14% 3 months or longer 84% 4 months or longer 78% 5
Slide 36: DAZZLE Disease Activity Assessment Criteria vs Phase 1b
How do DAZZLE Study Disease Activity Assessment Criteria Compare to Phase 1b? Parameters Phase 1b Study1 DAZZLE study2 Change Increase in CST ≥75 µm with a Increase in CST ≥50 µm with a Visual and Tighter CST control decrease in BCVA of ≥ 5 letters decrease in BCVA of ≥ 5 letters anatomical compared
Slide 37: DAZZLE Protocol Optimization
DAZZLE protocol optimization ▪ Building from the exploratory Phase 1b, DAZZLE maintains consistency of key features while further optimizing protocol design 1. Similar patient population – treatment naïve wAMD (~80% from USA) 2. Tighter dosing interval ranging – from Q4W-Q24W to Q12W-Q20W 3. Tighter
Slide 38: DME Year 1 Data
KSI-301 Phase 1b DME Year 1 Data 38
Slide 39: Efficacy of KSI-301 in DME
Efficacy of KSI-301 in DME Change from baseline to Week 52 in mean BCVA & OCT 80 ETDRS letters 75 BCVA 70 +7.6 65 ⁓20/32 60 0 4 8 12 16 20 24 Weeks 28 32 36 40 44 48 52 500 450 OCT CST microns 400 350 -136 300 N=32 250 3.0 1.0 Loading doses Individualized doses mean injections Interim data; 2.5 & 5
Slide 40: Durability of KSI-301 in DME
Durability of KSI-301 in DME 90% of patients received 2 or fewer retreatments in Year 1 100 50% of patients did not require Percentage of patients (%) Mean injections 4.0 in Year 1 80 any retreatment Individualized 60 1.0 doses 50.0 40 Monthly loading 3.0 doses 21.9 18.8 20 KSI-301 6.3 3.1 0.0 0.0 0
Slide 41: Durability of KSI-301 in DME: Retreatment Intervals
Durability of KSI-301 in DME Distribution of retreatment intervals at Year 1 100 69% of patients were on a 6-month or longer Percentage of patients (%) 80 68.8 treatment-free interval 60 at Year 1 40 20 9.4 9.4 3.1 6.3 3.1 0 1 2 3 4 5 6 months month months months months months or longer Treatment in
Slide 42: KSI-301 in DME: Loading Doses Provide Sustained Disease Control
KSI-301 in DME: 3 loading doses can provide sustained disease control of 3 to 6+ months Loading Year 1 Year 2 Overall Time on Study (weeks) 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Interval at Year 1* n=32 1 KSI-301 3 1 month 3% 2.5 mg 5 7 (n=9) 9 2 months 3% 1 3 3 months or longer 94% 5 KSI-301 7 4
Slide 43: 6-Month Disease Control in Proliferative Diabetic Retinopathy
6-month disease control after only 3 loading doses is also seen in proliferative diabetic retinopathy DAY 1 WEEK 12 WEEK 72 Proliferative DR (DRSS 71) Non-Proliferative DR (DRSS 53) Non-Proliferative DR (DRSS 53) KSI-301 Two 5 mg additional 3 loading doses doses PDR Regression from PDR to NPDR Fast
Slide 44: Case Example: No Retreatments for 12 Months in DME
Case Example: No Retreatments for 12 Months After Loading Phase KSI-301 in DME 3 Loading doses Day 1 Day 1 (Pre-Treatment) Week 4 Week 8 Week 12 1 month after 3 OCT Images loading doses From Phase 1b Study +3 letters 3 total injections in Year 1 6 months after 3 Week 32 loading doses +7 letters 12 m
Slide 45: Benchmarking in Treatment-Naïve DME
Benchmarking in treatment-naïve DME: KSI-301 Phase 1b “Generation 2.0” durability compared to Faricimab YOSEMITE / RHINE 75 Faricimab YOSEMITE / RHINE KSI-301 Phase 1b Study (Year 1) On Each Treatment Interval (%) 60 Proportion of Patients 45 30 15 0 4 8 12 16 20 24 Treatment Interval (Weeks) 1. Ang
Slide 46: Benchmarking: KSI-301 Phase 1b DME Data
Benchmarking: KSI-301 Phase 1b DME data “Generation 2.0” durability compared to Eylea Year 1 Average number of injections required 9.2 8.0 Maintenance Doses 3.2 4.0 4.0 1.0 Maintenance Dose Monthly Loading Doses 6.0 4.0 3.0 Monthly Loading Doses Eylea - Mean Faricimab KSI-301 (N=221)1 PTI - Median P
Slide 47: GLEAM and GLIMMER Studies: Dosing as Infrequently as Every 24 Weeks
KSI-301 Phase 3 DME GLEAM and GLIMMER Studies Dosing with KSI-301 as infrequently as every 24 weeks1 DME – Phase 1b GLEAM-GLIMMER pivotal studies evaluate Percentage individualized dosing of every 8, 12, 16, 20 or 24 weeks, Interval at Year 1* after only 3 loading doses (n= 32) 1 month 3% 2 months 3
Slide 48: GLEAM & GLIMMER Disease Activity Criteria vs Phase 1b
How do GLEAM & GLIMMER Studies Disease Activity Assessment Criteria Compare to Phase 1b? Parameters Phase 1b Study1 GLEAM & GLIMMER Studies Change Increase in OCT CST ≥ 50 µm compared to Tighter and Increase in CST ≥75 µm with a lowest previous measurement and a dynamic Visual and decrease in BCVA o
Slide 49: GLEAM & GLIMMER Phase 3 Protocol Optimization
GLEAM & GLIMMER Phase 3 protocol optimization ▪ Building from the exploratory Phase 1b, GLEAM & GLIMMER maintain consistency of key features while further optimizing protocol designs 1. Similar patient population – treatment naïve DME (~80% from USA) 2. Proactive tighter dosing interval ranging – fr
Slide 50: RVO Year 1 Data
KSI-301 Phase 1b RVO Year 1 Data 50
Slide 51: Efficacy of KSI-301 in RVO
Efficacy of KSI-301 in RVO Change from baseline to Week 52 in mean BCVA & OCT 80 ETDRS letters 75 70 +22.2 BCVA 65 ⁓20/32 60 55 50 0 4 8 12 16 20 24 Weeks28 32 36 40 44 48 52 750 650 OCT CST microns 550 450 BRVO n= 19 CRVO n= 15 -357 350 250 N=34 3.0 1.7 Loading doses Individualized doses mean injec
Slide 52: Durability of KSI-301 in RVO
Durability of KSI-301 in RVO 72% of patients received 2 or fewer retreatments in Year 1 100 Percentage of patients (%) Mean injections 4.7 in Year 1 80 Only 28% of patients Individualized 60 1.7 doses required more than 5 total injections in Year 1* 40 31.3 Monthly loading 3.0 doses 25.0 20 15.6 12.
Slide 53: Durability of KSI-301 in RVO: Retreatment Intervals
Durability of KSI-301 in RVO Distribution of retreatment intervals at Year 1 100 66% of patients were on a 6-month or longer Percentage of patients (%) 80 treatment-free interval 65.6 60 at Year 1 40 20 12.5 9.4 3.1 6.3 3.1 0 1 2 3 4 5 6 months month months months months months or longer Treatment i
Slide 54: KSI-301 in RVO: Loading Doses Provide Sustained Disease Control
KSI-301 in RVO: 3 loading doses can provide sustained disease control of 2 to 6+ months Loading Year 1 Year 2 Overall Time on Study (weeks) 0 8 16 24 32 40 48 56 64 72 80 88 96 104 Interval at Year 1* n=32 1 KSI-301 3 1 month 3% 2.5 mg 5 (n=9) 7 2 months 9% 9 1 3 3 months or longer 87% 5 KSI-301 7 4
Slide 55: Controlling Severe CRVO Cases with Only 2 Loading Doses
Is it possible to control the most severe CRVO cases with only 2 loading doses? Case Example of KSI-301 in the Phase 1b Study Day 1 1202 microns Week 1 1 week after 1 dose 597 microns +14 letters Week 4 1 month after 1 dose 416 microns +23 letters Week 8 1 month after 2 doses 260 microns +23 letters
Slide 56: Benchmarking: KSI-301 Phase 1b RVO Data
Benchmarking: KSI-301 Phase 1b RVO data “Generation 2.0” durability compared to Eylea Year 1 Mean number of injections required 8.6 Maintenance doses 2.6 4.7 1.7 Maintenance doses Monthly loading doses 6.0 3.0 Monthly loading doses Eylea KSI-301 (n=221)1 Phase 1b study (n=32)2 1. Injections averaged
Slide 57: BEACON Study: Two Loading Doses Plus Every 8 Weeks
KSI-301 Phase 3 RVO BEACON Study Two loading doses with KSI-301 + every 8 weeks RVO – Phase 1b BEACON pivotal study evaluates two loading doses and Percentage every 8-week dosing, followed by individualized dosing Interval at Year 1* (n= 34) 1 month 3% 2 months 9% 3 months or longer 87% 4 months or
Slide 58: BEACON Disease Activity Assessment Criteria vs Phase 1b
How do BEACON Study Disease Activity Assessment Criteria Compare to Phase 1b? Parameters Phase 1b Study1 BEACON Study2 Change Increase in OCT CST ≥ 50 µm compared to Tighter and Increase in CST ≥75 µm with a lowest previous measurement and a dynamic Visual and decrease in BCVA of ≥ 5 letters decreas
Slide 59: BEACON Phase 3 Protocol Optimization
BEACON Phase 3 protocol optimization ▪ Building from the exploratory Phase 1b, BEACON maintains consistency of key features while further optimizing study protocol 1. Similar patient population – treatment naïve RVO (~80% from USA) 2. Proactive tighter dosing interval – from uncapped to fixed q2-mon
Slide 60: Safety
KSI-301 Phase 1b Safety 60
Slide 61: Safety of KSI-301: Excellent Safety Profile
Safety of KSI-301: Excellent safety profile 130 710 168 + 121 96 Subjects dosed Total doses Patient-years Completed the Phase 1b subjects at Week 12 or later that Across the Phase 1a/1b program loading phase in have received all three loading doses plus Phase 1b at least one additional retreatment ▪
Slide 62: Where We Are Today
K S I - 30 1 C L I N I C A L E X P E R IE N C E Clinical data from ~2,000 injections in ~500 patients representing ~350 patient-years of exposure in representative populations in wAMD, DME and RVO ▪ Safety: Tracking with current standard of care (Lucentis, Eylea) ▪ Efficacy: Vision & retinal anatomy
Slide 63: The Ophthalmology Medicines Company
THE OPHTHALMOLOGY MEDICINES COMPANY
Kodiak Sciences — Barclays Global Healthcare Conference 2021 on 6ix